文献速递肝病

白人瘦型非酒精性脂肪性肝病患者的长期预后与非瘦型相似:需重新评估基于BMI的策略

Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?
PubMed 文献 · Gut · 2021-02-04

该研究纳入四国1339例活检证实的非酒精性脂肪性肝病(NAFLD)患者,比较瘦型(BMI<25)与非瘦型(BMI≥25)的长期预后。瘦型占14.4%,其组织学病变较轻且糖尿病患病率较低,但随访94个月后肝脏相关事件发生率与生存率与非瘦型无显著差异。结论提示瘦型NAFLD仍可进展为晚期肝病并出现代谢合并症及心血管疾病。

要点

  • 瘦型NAFLD占活检队列14.4%,组织学病变较轻但长期肝脏事件风险与非瘦型相似。
  • 瘦型患者糖尿病患病率显著低于非瘦型,但PNPLA3 I148M变异频率无差异。
  • 瘦型NAFLD可独立于体重增加进展为晚期肝病及肝外疾病,需重新评估BMI驱动策略。

核心结论

  • 白人瘦型NAFLD患者可进展为晚期肝病、发生代谢合并症及心血管疾病和肝脏相关死亡,独立于纵向进展为肥胖和PNPLA3基因型。

研究设计与样本

  • 研究队列包括来自意大利、英国、西班牙和澳大利亚四个国家的1339例活检证实的NAFLD患者,按BMI<25 kg/m2和≥25 kg/m2分为瘦型和非瘦型。

主要发现

  • 瘦型患者占队列14.4%,其中89%为意大利裔。
  • 瘦型vs非瘦型:非酒精性脂肪性肝炎54.1% vs 71.2%(p<0.001),晚期纤维化10.1% vs 25.2%(p<0.001),糖尿病9.2% vs 31.4%(p<0.001)。
  • PNPLA3 I148M变异频率在瘦型与非瘦型间无显著差异(p=0.57)。
  • 中位随访94个月(>10 483人年),瘦型vs非瘦型肝脏相关事件发生率4.7% vs 7.7%(p=0.37),生存率无差异(p=0.069)。

临床怎么用

  • 临床应认识到瘦型NAFLD患者同样可能进展为晚期肝病和发生代谢合并症,不能仅依据BMI评估风险。

局限性

  • 瘦型患者 predominantly 为意大利裔(89%),可能限制结果外推性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis of Caucasian lean subjects with NAFLD. DESIGN: The study cohort comprises 1339 biopsy-proven NAFLD subjects from four countries (Italy, UK, Spain and Australia), stratified into lean and non-lean (body mass index (BMI) </≥25 kg/m2). Liver/non-liver-related events and survival free of transplantation were recorded during the follow-up, compared by log-rank testing and reported by adjusted HR. RESULTS: Lean patients represented 14.4% of the cohort and were predominantly of Italian origin (89%). They had less severe histological disease (lean vs non-lean: non-alcoholic steatohepatitis 54.1% vs 71.2% p<0.001; advanced fibrosis 10.1% vs 25.2% p<0.001), lower prevalence of diabetes (9.2% vs 31.4%, p<0.001), but no significant differences in the prevalence of the PNPLA3 I148M variant (p=0.57). During a median follow-up of 94 months (>10 483 person-years), 4.7% of lean vs 7.7% of non-lean patients reported liver-related events (p=0.37). No difference in survival was observed compared with non-lean NAFLD (p=0.069). CONCLUSIONS: Caucasian lean subjects with NAFLD may progress to advanced liver disease, develop metabolic comorbidities and experience cardiovascular disease (CVD) as well as liver-related mortality, independent of longitudinal progression to obesity and PNPLA3 genotype. These patients represent one end of a wide spectrum of phenotypic expression of NAFLD where the disease manifests at lower overall BMI thresholds. LAY SUMMARY: NAFLD may affect and progress in both obese and lean individuals. Lean subjects are predominantly males, have a younger age at diagnosis and are more prevalent in some geographic areas. During the follow-up, lean subjects can develop hepatic and extrahepatic disease, including metabolic comorbidities, in the absence of weight gain. These patients represent one end of a wide spectrum of phenotypic expression of NAFLD.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Younes R, Govaere O, Petta S, et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? Gut. 2021. PMID: 33541866. doi:10.1136/gutjnl-2020-322564

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。